BRIEF—AnGes links with Kamada on gene therapy

Osaka, Japan-based-based biotech AnGes has signed a memorandum of understanding (MoU) with the Israeli biotech firm Kamada.

The goal is to grant Kamada exclusive distribution rights in Israel to AnGes's HGF gene therapy for critical limb ischemia.

A licensing deal is expected after the therapy gets a New Drug Application (NDA) approval from Japan's Ministry of Health, Labor and Welfare (MHLW).

Financial terms of the collaboration are not disclosed,

The Japan and US distribution rights were granted to Mitsubishi Tanabe Pharma.

AnGes continues to seek partnerships globally.